Patents by Inventor Jiaqiang Dong

Jiaqiang Dong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors
    Patent number: 11639355
    Abstract: Disclosed is a novel class of MDM2-p53 inhibitor compounds having an imidaxopyrolone structure, and specifically disclosed are compounds represented by formulas (I-1) and (I-2) and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: May 2, 2023
    Assignees: LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD., SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD., MEDSHINE DISCOVERY INC.
    Inventors: Kevin X Chen, Xiaobing Yan, Jianglei Huang, Yuekun Nie, Guoping Hu, Jian Li, Shuhui Chen, Jiaqiang Dong, Tie-Lin Wang
  • Crystal Form of Quinazolinone Compound and Preparation Method Therefor
    Publication number: 20220213060
    Abstract: The present invention relates to a crystal form of a compound of formula (I), which acts as a PI3K? inhibitor, and a preparation method therefor, and the use thereof in the preparation of a medicine for treating solid tumors.
    Type: Application
    Filed: May 13, 2020
    Publication date: July 7, 2022
    Inventors: Jingjie Huang, Yijie Yin, Ting Yao, Tao Yu, Chengde Wu, Jiaqiang Dong, Bin Shi, Wei Tang, Wenqian Yang, Tie-Lin Wang
  • Salt Form of Estrogen Receptor Downregulator, Crystalline Form Thereof, and Preparation Method Therefor
    Publication number: 20220017463
    Abstract: Provided are a salt form of an estrogen receptor down-regulator, a crystalline form thereof, and a preparation method therefor.
    Type: Application
    Filed: October 17, 2019
    Publication date: January 20, 2022
    Inventors: Huijun HE, Shenyi SHI, Jianyu LU, Charles Z. DING, Lihong HU, Bin SHI, Wenqian YANG, Jiaqiang DONG, Tie-Lin WANG
  • IMIDAXOPYROLONE COMPOUND AND APPLICATION THEREOF
    Publication number: 20210230164
    Abstract: Disclosed is a novel class of MDM2-p53 inhibitor compounds having an imidaxopyrolone structure, and specifically disclosed are compounds represented by formulas (I-1) and (I-2) and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: March 12, 2019
    Publication date: July 29, 2021
    Inventors: Kevin X CHEN, Xiaobing YAN, Jianglei HUANG, Yuekun NIE, Guoping HU, Jian LI, Shuhui CHEN, Jiaqiang DONG, Tie-Lin WANG
  • Crystal form of estrogen receptor inhibitor and preparation method therefor
    Patent number: 11034653
    Abstract: Disclosed are a crystal form of an estrogen receptor inhibitor and a preparation method therefor, in particular disclosed are a crystal form A of a compound of formula (I) and a preparation method therefor, and the use of the crystal form in the preparation of a drug for treating breast cancer.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: June 15, 2021
    Assignees: LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD., SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.
    Inventors: Huijun He, Jianyu Lu, Weidong Li, Shenyi Shi, Zhijuan Chen, Charles Z. Ding, Lihong Hu, Tie-Lin Wang, Jiaqiang Dong
  • Quinazolinone Compound and Application Thereof
    Publication number: 20200317660
    Abstract: The present invention relates to a series of quinazolinone compounds and applications thereof as PI3K? inhibitors. In particular, the present invention relates to a compound shown in formula (I) and a tautomer or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 12, 2018
    Publication date: October 8, 2020
    Inventors: Chengde WU, Jingjie HUANG, Tao YU, Jiaqiang DONG, Tie-Lin WANG, Jie LI, Jian LI, Shuhui CHEN
  • Indolo substituted piperidine compound as estrogen receptor down-regulator
    Patent number: 10774081
    Abstract: Disclosed in the present invention is a type of indole substituted piperidine compounds as an estrogen receptor down-regulator. Specifically disclosed are a compound as shown in formula (I), a pharmaceutically acceptable salt, hydrate or prodrug thereof, a preparation method therefor, a pharmaceutical composition thereof, and a use thereof as an estrogen receptor down-regulator in the treatment of estrogen receptor positive breast cancers.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: September 15, 2020
    Assignees: LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD., SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.
    Inventors: Jianyu Lu, Charles Z. Ding, Xu Zeng, Huijun He, Shuhui Chen, Lihong Hu, Jiaqiang Dong, Tie-Lin Wang
  • CRYSTAL FORM OF ESTROGEN RECEPTOR INHIBITOR AND PREPARATION METHOD THEREFOR
    Publication number: 20200247748
    Abstract: Disclosed are a crystal form of an estrogen receptor inhibitor and a preparation method therefor, in particular disclosed are a crystal form A of a compound of formula (I) and a preparation method therefor, and the use of the crystal form in the preparation of a drug for treating breast cancer.
    Type: Application
    Filed: September 25, 2018
    Publication date: August 6, 2020
    Inventors: Huijun HE, Jianyu LU, Weidong LI, Shenyi SHI, Zhijuan CHEN, Charles Z. DING, Lihong HU, Tie-Lin WANG, Jiaqiang DONG
  • Substituted-indole-compounds as estrogen receptor down-regulators
    Patent number: 10519143
    Abstract: Disclosed is a new indole compound, in particular, the compound as shown in formula (I), and a preparation method, pharmaceutical composition and use thereof as an estrogen receptor down-regulator in preparing drugs for treating estrogen receptor-positive breast cancer.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: December 31, 2019
    Assignee: LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD.
    Inventors: Jianyu Lu, Charles Z. Ding, Lihong Hu, Huijun He, Shuhui Chen, Jiaqiang Dong, Tie-Lin Wang
  • INDOLO SUBSTITUTED PIPERIDINE COMPOUND AS ESTROGEN RECEPTOR DEGRADING AGENT
    Publication number: 20190337938
    Abstract: Disclosed in the present invention is a type of indole substituted piperidine compounds as an estrogen receptor degrading agent. Specifically disclosed are a compound as shown in formula (I), a pharmaceutically acceptable salt, hydrate or prodrug thereof, a preparation method therefor, a pharmaceutical composition thereof, and a use thereof as an estrogen receptor degrading agent in the treatment of estrogen receptor positive breast cancers.
    Type: Application
    Filed: October 30, 2017
    Publication date: November 7, 2019
    Applicants: LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD., SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.
    Inventors: Jianyu LU, Charles Z. DING, Xu ZENG, Huijun HE, Shuhui CHEN, Lihong HU, Jiaqiang DONG, Tie-Lin WANG
  • NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF
    Publication number: 20190284192
    Abstract: Disclosed in the present invention are a nitrogenous macrocyclic compound, a preparation method therefor, a pharmaceutical composition and an application thereof. The present invention provides a nitrogenous macrocyclic compound represented by formula III-0, a tautomer thereof, an optical isomer thereof, a hydrate thereof, a solvate thereof, a pharmacologically acceptable salt thereof, or a prodrug thereof. The compound can be effectively bond with bromodomains of a BET family: BRD4, BRD3, BRD2, and BRDT, so as to adjust transcription of a downstream gene c-myc and a related target gene thereof, and further to adjust a downstream signal path and play a particular role, comprising treating diseases such as inflammatory diseases, cancers, and AIDS.
    Type: Application
    Filed: November 10, 2017
    Publication date: September 19, 2019
    Inventors: Yonghan HU, Dongmei CAI, Jiuxiang ZHU, Ping DONG, Jiaqiang DONG, Tie-Lin WANG
  • SUBSTITUTED-INDOLE-COMPOUNDS AS ESTROGEN RECEPTOR DOWN-REGULATORS
    Publication number: 20190106414
    Abstract: Disclosed is a new indole compound, in particular, the compound as shown in formula (I), and a preparation method, pharmaceutical composition and use thereof as an estrogen receptor down-regulator in preparing drugs for treating estrogen receptor-positive breast cancer.
    Type: Application
    Filed: March 24, 2017
    Publication date: April 11, 2019
    Inventors: Jianyu LU, Charles Z. DING, Lihong HU, Huijun HE, Shuhui CHEN, Jiaqiang DONG, Tie-Lin WANG
  • ALK kinase inhibitor, and preparation method and uses thereof
    Patent number: 10023593
    Abstract: An ALK kinase inhibitor compound as represented by Formula I, pharmaceutical composition containing the compound, and preparation method and use thereof in the preparation of drugs serving as an ALK inhibitor for treating cancer.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: July 17, 2018
    Assignee: Beijing Pearl Biotechnology Limited Liability Company
    Inventors: Jiaqiang Dong, Boyu Zhong, Hongbin Yuan, Chuan Shih, Shaosong Chu, Deyi Zhang, Ruihao Zhang
  • ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USES THEREOF
    Publication number: 20170247392
    Abstract: An ALK kinase inhibitor compound as represented by Formula I, pharmaceutical composition containing the compound, and preparation method and use thereof in the preparation of drugs serving as an ALK inhibitor for treating cancer.
    Type: Application
    Filed: May 29, 2015
    Publication date: August 31, 2017
    Inventors: Jiaqiang DONG, Boyu ZHONG, Hongbin YUAN, Chuan SHIH, Shaosong CHU, Deyi ZHANG, Ruihao ZHANG
  • Aryl-isoxazol-4-yl-imidazo[1,5-a]pyridine derivatives
    Patent number: 7399769
    Abstract: The present invention is concerned with aryl-isoxazol-4-yl-imidazo[1,5-a]pyridine derivatives of formula wherein: R1, R2, and R3 are as defined herein and pharmaceutically acceptable acid addition salts thereof. These compounds have high affinity and selectivity for GABA A ?5 receptor binding sites. The invention also relates to methods for enhancing cognition and treating cognitive disorders like Alzheimer's disease.
    Type: Grant
    Filed: December 18, 2006
    Date of Patent: July 15, 2008
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bernd Buettelmann, Jiaqiang Dong, Bo Han, Henner Knust, Andrew Thomas
  • Aryl-isoxazol-4-yl-imidazo[1,5-a]pyridine derivatives
    Publication number: 20070191421
    Abstract: The present invention is concerned with aryl-isoxazol-4-yl-imidazo[1,5-a]pyridine derivatives of formula wherein: R1, R2, and R3 are as defined herein and pharmaceutically acceptable acid addition salts thereof. These compounds have high affinity and selectivity for GABA A ?5 receptor binding sites. The invention also relates to methods for enhancing cognition and treating cognitive disorders like Alzheimer's disease.
    Type: Application
    Filed: December 18, 2006
    Publication date: August 16, 2007
    Inventors: Bernd Buettelmann, Jiaqiang Dong, Bo Han, Henner Knust, Andrew Thomas